{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:27Z","timestamp":1790270727969,"version":"4.1.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.clindermatol.2025.09.021","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:40:53Z","timestamp":1759538453000},"page":"762-765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Lymphocytic and granulomatous cutaneous small-vessel vasculitis after polyadenosine diphosphate\u2013ribose polymerase inhibitor therapy"],"prefix":"10.1016","volume":"43","author":[{"given":"Carla","family":"Stephan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2025.09.021_bib0001","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: update on PARP inhibitors [published correction appears in Ann Oncol. 2021 Aug;32:1066-1067]","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0002","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.molonc.2011.07.001","article-title":"The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings","volume":"5","author":"Helleday","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0003","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2017;390:1948]","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0004","article-title":"A novel adverse event associated with Olaparib therapy in a patient with metastatic breast cancer","volume":"2018","author":"Wheelden","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0005","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1111\/1346-8138.15749","article-title":"Cutaneous arteritis during olaparib treatment for ovarian cancer","volume":"48","author":"Iinuma","year":"2021","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0006","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/DDDT.S150846","article-title":"Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach","volume":"12","author":"Zaffini","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0007","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0008","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ajco.13584","article-title":"Olaparib dose re-escalation in ovarian cancer patients who experienced severe and\/or uncommon adverse events: a case series","volume":"3","author":"Ngu","year":"2021","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0009","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1684\/ejd.2022.4343","article-title":"Olaparib-induced cutaneous vasculitis in a patient with recurrent ovarian cancer","volume":"32","author":"Fukui","year":"2022","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920944116","article-title":"PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers","volume":"12","author":"Lee","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0011","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.4049\/jimmunol.177.9.6489","volume":"177","author":"Oumouna","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0012","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-3083.2005.01570.x","article-title":"Immunology of cutaneous vasculitis associated with both etanercept and infliximab","volume":"61","author":"Srivastava","year":"2005","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.clindermatol.2025.09.021_bib0013","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/1529-0131(199904)42:4<742::AID-ANR18>3.0.CO;2-I","article-title":"Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation","volume":"42","author":"Csernok","year":"1999","journal-title":"Arthritis Rheum"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25002548?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X25002548?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T13:29:31Z","timestamp":1767878971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X25002548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0738081X25002548"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.09.021","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphocytic and granulomatous cutaneous small-vessel vasculitis after polyadenosine diphosphate\u2013ribose polymerase inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2025.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}